SenzaGen to present at LIVe 2018 in Nice, July 5th-6th

On July 5th-6th, SenzaGen will be an attending sponsor at LIVe 2018 (Lung In Vitro event for innovative & predictive models) in Nice, France. The meeting intends to be a unique exchange platform for scientists interested in in vitro respiratory researches, stakeholders from academia, pharma, biotech, chemical, tobacco, consumer goods, medical devices industries, CROs and […]

On July 5th-6th, SenzaGen will be an attending sponsor at LIVe 2018 (Lung In Vitro event for innovative & predictive models) in Nice, France. The meeting intends to be a unique exchange platform for scientists interested in in vitro respiratory researches, stakeholders from academia, pharma, biotech, chemical, tobacco, consumer goods, medical devices industries, CROs and regulatory agencies.

LIVe 2018 focuses on predictive in vitro lung models designed for basic research, efficacy, sensitization and toxicity testing. It aims to present the state-of-art of in vitro lung models, and to map out the route for its future development and use.

Henrik Johansson, PhD, Senior scientist at SenzaGen, will be giving a key note presentation on the abstract “How do we incorporate recent developments in Big Data analysis and Machine Learning technologies in the field of Toxicology?” on July 6th, opening the 6th event session, “Think Different”. This will be followed by a panel discussion, including Henrik Johansson, regarding “Next Horizon for in vitro lung modeling”.

SenzaGen will also be presenting a poster with the title “GARDair – A novel assay for assessment of chemical respiratory sensitizers based on a genomic platform”. The poster summarizes SenzaGen’s findings so far regarding Horizon 2020.

If you will be attending LIVe 2018 as well, please come visit SenzaGen’s booth. Hope to see you there!

Link to conference website

Link to programme

 

Vi anställer! – Är du vår nya kollega?

Laboratorieingenjör Vi behöver förstärka vårt team med en engagerad och strukturerad person som trivs med rutinarbete i en dynamisk verksamhet! Vill du arbeta med produkter som förbättrar människors hälsa utan att använda djurförsök? Då är tjänsten som laboratorieingenjör hos oss något för dig! Om SenzaGen SenzaGen AB är ett publikt Biotech-bolag som erbjuder och utvecklar […]

Laboratorieingenjör

Vi behöver förstärka vårt team med en engagerad och strukturerad person som trivs med rutinarbete i en dynamisk verksamhet!

Vill du arbeta med produkter som förbättrar människors hälsa utan att använda djurförsök? Då är tjänsten som laboratorieingenjör hos oss något för dig!

Om SenzaGen

SenzaGen AB är ett publikt Biotech-bolag som erbjuder och utvecklar den nya generationens djurfria testmetoder för bedömning av immunotoxikologiska egenskaper hos bl a kemikalier och komplexa blandningar. SenzaGen AB bildades 2010 som ett spin-out bolag från Institutionen för Immunteknologi, Lunds Universitet. Idag har bolaget 20 anställda och våra kunder finns inom kosmetika-, kemikalie- och läkemedelsindustrin. SenzaGen har mottagit flertalet utmärkelser såsom plats på Ny Teknik och Affärsvärldens 33-lista två år i rad, PWCs SKAPA Innovationspris samt Dagens Industris Gasellsprånget. SenzaGen noterades på Nasdaq First North i september 2017 och vi finns på Medicon Village i Lund.

Om GARD

GARD (Genomic Allergen Rapid Detection) är en state-of-the-art in vitro-plattform som med hjälp av patenterade genomiska biomarkörsignaturer och maskininlärning bedömer kemiska substansers kapacitet att orsaka hud- eller luftvägsallergi. Testet är unikt då det efterliknar människans immunreaktion.

SenzaGens ledande produkt, GARDskin, är en vetenskapligt granskad analysmetod med en mycket hög noggrannhet på >90%. Tillsammans med vår nästkommande produkt, GARDpotency, genomgår GARDskin för närvarande en validering hos OECD och ECVAM.

Arbetsuppgifter

  • Delta i kund- och utvecklingsprojekt som laborativ resurs
  • Utföra laboratoriearbete enligt gällande kvalitetssystem och inom överenskomna tidsramar
  • Dokumentera och sammanställa analysdata
  • Köpa in förbrukningsmaterial till laboratoriet
  • Ha ansvar för den dagliga driften på laboratoriet
  • Aktivt deltaga i interna möten

Kvalifikationer

Du har en examen som biomedicinsk analytiker eller motsvarande med flera års erfarenhet av laboratoriearbete i cellbiologisk miljö och är van att genomföra analyser enligt metodbeskrivning. Kunskaper inom cellodling, flödescytometri och RNA-hantering är särskilt meriterande. Du besitter naturligt ett kvalitetstänk. Du är kommunikativ i svenska och engelska i tal och skrift samt är van att arbeta med Officepaketet. Som person är du strukturerad, noggrann och har stort fokus på att leverera arbete med hög kvalitet och i tid. Du känner ansvar och engagemang för din uppgift och du är flexibel och trivs att arbeta i en grupp där alla strävar mot samma mål. Då vi är ett litet sammansvetsat team lägger vi stor vikt på lämplighet och personlighet.

Vi erbjuder

Som anställd hos SenzaGen erbjuds du att arbeta i en kreativ och engagerande miljö och vara del i ett innovativt företag som ligger i frontlinjen inom in vitro-metodik och sensibilisering. Företaget befinner sig i en spännande fas där alla strävar mot att ta företaget och vår vision framåt! Tjänsten är en 6 månaders provanställning med mål att övergå i en tillsvidareanställning. Tjänsten är heltid (40 timmar/vecka) med placering hos SenzaGen på Medicon Village i Lund.

Ansökan

Du ansöker till tjänsten genom att e-posta ditt CV och personliga brev till ansokan@senzagen.com senast 2018-07-15. Vi hanterar ansökningarna löpande så vänligen skicka din ansökan snarast!

Kontaktperson är Maria Agemark (0707-713114 eller maria.agemark@senzagen.com) men notera att din ansökan behöver registreras hos ansokan@senzagen.com

ANSÖKAN SOM PDF

Seminar at the Swedish Parliamentary Animal Protection Forum in collaboration with Djurens Rätt (Animal Rights), The Body Shop and Cruelty Free International

On Wednesday May 23rd 2018, SenzaGen’s CEO Anki Malmborg Hager participated in a breakfast seminar at the Swedish Parliament organized by the Parliamentary Animal Protection Forum, Birgitta Ohlsson (L) and Jens Holm (V), in collaboration with Djurens Rätt (Animal Rights), The Body Shop and Cruelty Free International. The seminar was organized to provide on-site information […]

On Wednesday May 23rd 2018, SenzaGen’s CEO Anki Malmborg Hager participated in a breakfast seminar at the Swedish Parliament organized by the Parliamentary Animal Protection Forum, Birgitta Ohlsson (L) and Jens Holm (V), in collaboration with Djurens Rätt (Animal Rights), The Body Shop and Cruelty Free International. The seminar was organized to provide on-site information about Swedish politicians’ views on a global ban of animal testing in cosmetics, and Anki gave a presentation on animal-free methods for the testing of chemicals and cosmetics.

A few weeks ago, the EU Parliament agreed (by 620 votes to 14) that the European Union should work towards a global ban of animal testing of cosmetic products. But in many parts of the world there are still no laws to ban animal testing of cosmetic products and ingredients. This despite the availability of approved and scientifically validated more efficient and accurate non-animal based methods that are both faster and often cheaper.

Cruelty Free International is currently running a worldwide campaign together with The Body Shop under the hashtag #Foreveragainstanimaltesting to put an end to animal testing globally, forever. There was considerable interest at this seminar in SenzaGen’s in vitro method, which is based on human cells instead of animals.

“The fact that cosmetics and chemicals are still tested on animals in large parts of the world is really hard to understand when new methods are much more accurate. On average, animal tests have an accuracy of about 72% and the test we developed, GARDskin, offers an accuracy of more than 90%. And apart from the difference in accuracy, we are getting answers to how the human immune system is affected rather than how mice are affected,” says Anki Malmborg Hager, SenzaGen’s CEO.

The seminar is part of a very important initiative to pursue the issue of animal experiments both politically and via opinion, and, above all, to demand safer testing of chemical ingredients in the products that surround us in everyday life.

“It has been a wonderful opportunity for us to participate in this seminar and we look forward to being able to continue contributing to the entire project in the best way we can,” says Anki Malmborg Hager, CEO, SenzaGen.

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

New opportunity to join a free presentation on Sensitization testing using GARD™

Don’t miss this new opportunity to join a free presentation on Sensitization testing using GARD™ “Sensitization testing and hazard assessment using functional genomics with GARD™” A new presentation has been scheduled to Wed, May 30, 2018 1:00 PM – 2:00 PM EDT (19:00 CET) This free webinar set for US time zone will give insight […]

Don’t miss this new opportunity to join a free presentation on Sensitization testing using GARD™

“Sensitization testing and hazard assessment using functional genomics with GARD™”

A new presentation has been scheduled to Wed, May 30, 2018 1:00 PM – 2:00 PM EDT (19:00 CET)

This free webinar set for US time zone will give insight into the latest in vitro technology using human cell lines and genomics for skin and respiratory sensitization, potency classification CLP 1A and 1B of skin sensitizers and with ability to test complex mixtures. A thorough explanation of the GARD™ technology, how it compares to other in vitro skin sensitization assays and how it is a highly reliable method for safety assessment, all industries.
Sensitization testing based on functional genomics

The webinar forum gives you a good chance to ask questions after the presentation.

We are very much looking forward to meeting you virtually in the webinar platform!

Read more and register on our website in the Event calendar

SenzaGen invited to speak at the Swedish Parliament Breakfast seminar Fråga Makten! (Ask the power) about how we stop animal testing in cosmetics

The Swedish Parliament’s Animal Protection Forum and Birgitta Ohlsson (L) in collaboration with Djurens Rätt (Animal Rights), The Body Shop and Cruelty Free International invite to a breakfast seminar to stop animal testing in cosmetics – everywhere in the world, forever. SenzaGen’s CEO, Anki Malmborg Hager, is invited as key person to give the participants […]

The Swedish Parliament’s Animal Protection Forum and Birgitta Ohlsson (L) in collaboration with Djurens Rätt (Animal Rights), The Body Shop and Cruelty Free International invite to a breakfast seminar to stop animal testing in cosmetics – everywhere in the world, forever.

SenzaGen’s CEO, Anki Malmborg Hager, is invited as key person to give the participants background on non-animal methods.

 

Participating Key Persons:
Jessie MacNeilBrown, Global Campaign Manager The Body Shop
Kerry Postlewight, Cruelty Free International
Camilla Björkbom, President Djurens rätt
Ann-Christin Malmborg Hager, CEO SenzaGen – Non-animal test methods
Jens Holm, Representative of the Swedish Parliament’s Animal Protection Forum (V)
Åsa Westlund, Head of Environment and Agriculture Committee (S)
Sofia Arkelsten (M)
Emma Nohrén (MP)
Birgitta Ohlsson, Representative of the Swedish Parliament’s Animal Protection Forum  (L)

 

Details:
Event: Breakfast seminar in the Swedish Parliament
Date: May 23

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

SenzaGen to present at Vator Securities Unicorn Summit on May 8, 2018

SenzaGen announces that the company will participate in the Vator Securities Unicorn Summit, which takes place in Stockholm in May. Anki Malmborg Hager, CEO, will present the company developments and SenzaGen’s ongoing and planned activities for commercialization of GARD – a technology platform that allows for replacement of animal experiments with genetic testing to assess […]

SenzaGen announces that the company will participate in the Vator Securities Unicorn Summit, which takes place in Stockholm in May. Anki Malmborg Hager, CEO, will present the company developments and SenzaGen’s ongoing and planned activities for commercialization of GARD – a technology platform that allows for replacement of animal experiments with genetic testing to assess whether the chemicals we come into contact with in our daily lives are allergenic.

Unicorn Summit is a capital market day organized by Vator Securities to bring together some of the most innovative and fast-growing Swedish life science companies with investors. More information about Vator Securities www.vatorsecurities.se

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability.

This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com

 

 

SenzaGen invites to a Live Session at the Facebook group “Aktier – Småbolagsjakten”

SenzaGen will host a live Question and Answer session with the management of the company May 16 between 19:00 – 20:00 CET “Aktier – Småbolagsjakten” is the largest Facebook group in the Nordic region, focusing on publicly traded small companies. The group has over 35 000 members. During the Live Session all questions and answers will […]

SenzaGen will host a live Question and Answer session with the management of the company May 16 between 19:00 – 20:00 CET

“Aktier – Småbolagsjakten” is the largest Facebook group in the Nordic region, focusing on publicly traded small companies. The group has over 35 000 members.

During the Live Session all questions and answers will be in English. Participants will have the opportunity to ask questions directly to company management including Chairman Carl Borrebaeck and CEO Anki Malmborg Hager.

To participate in the session, you must first become a member of the Facebook group “Aktier – Småbolagsjakten”. It is recommended that you submit a membership request at least one day in advance of the presentation to ensure you can participate in the event.

 

To join the group:

  1. Go to https://www.facebook.com/groups/smabolagsjakten
  2. Click the green “+ Join Group” button
  3. You will receive a notification on Facebook when your application to the group is accepted

 

For more information, please contact:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90 percent reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75 percent. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

 

SenzaGen AB are listed on Nasdaq First North in Stockholm and FNCA is the company’s Certified Adviser. For more information, please visit www.senzagen.com

Successful outcome at the Future of Swedish and Danish Life Science day

We wish to thank Kemivärlden Biotech and Medicon Village for Thursday’s event “The Future of Swedish and Danish Life Science”, many interesting areas within precision medicine and big data were covered, not least within genomics. Life sciences and information technologies have become more and more connected to make patient’s life better; a perfect example on […]

We wish to thank Kemivärlden Biotech and Medicon Village for Thursday’s event “The Future of Swedish and Danish Life Science”, many interesting areas within precision medicine and big data were covered, not least within genomics.

Life sciences and information technologies have become more and more connected to make patient’s life better; a perfect example on this is SenzaGen’s in vitro safety testing based on genomics. By argumenting on how the company’s GARD™ technology can improve patient’s life, and how the technology can contribute to establish a new industry standard for animal free safety testing, SenzaGen’s Chief Commercial Officer, Anna Chérouvrier Hansson, won the Dragons Den pitch at The Future of Swedish and Danish Life Science.

-We’re very happy and proud to be recognized as a game changer in the industry, contributing to a safer patient environment, says Anna.
The prize, a ticket to the One Nucleus Genesis conference in London will support SenzaGen’s development of coming closer to the goal of placing a new industry standard.

 

For more information
Anki Malmborg Hager, CEO
SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

Thank you for a great Society of Toxicology and ToxExpo 2018!

We would like to extend a great thank you to all customers, partners, friends and collaborators for a great SOT and ToxExpo 2018! We had record numbers both in the audience for the presentation, at the poster presentation on validation for OECD and at the booth. We are very happy and proud to see the […]

We would like to extend a great thank you to all customers, partners, friends and collaborators for a great SOT and ToxExpo 2018!

We had record numbers both in the audience for the presentation, at the poster presentation on validation for OECD and at the booth. We are very happy and proud to see the rapidly growing interest for SenzaGen and our GARD products and wish to thank you all for your shown interest!

A webinar with the presentation from SOT will be held for those interested on Tuesday March 27 at 11:30 am.

Presentation pdf available here

Poster on validation available here

Register for webinar here.
The presentation will be held in English

Thank you and we look forward to future collaborations!

 

For more information:
Anki Malmborg Hager, CEO
SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

 

 

 

Conclusive data on predictive performance of GARD™ in highly regarded scientific journal

SenzaGen announces today that research on the conformal prediction of the GARD™ assay has been published in the distinguished peer reviewed journal Toxicology in Vitro. The research presented in the publication proves that, as the first in vitro model for prediction of the skin sensitizing potential of chemicals, GARD™ is now capable of providing a […]

SenzaGen announces today that research on the conformal prediction of the GARD™ assay has been published in the distinguished peer reviewed journal Toxicology in Vitro. The research presented in the publication proves that, as the first in vitro model for prediction of the skin sensitizing potential of chemicals, GARD™ is now capable of providing a statistically valid measure of uncertainty for each individual prediction, thus allowing for classification of skin sensitizers with confidence. Consequently, GARD™ can meet the growing needs of high safety skin sensitization testing and particularly since there is now proof that all chemical reactivity domains, as well as pre- and pro-haptens are within GARD’s applicability domain. 

In the publication, Predicting skin sensitizers with confidence — Using conformal prediction to determine applicability domain of GARD™, a research group from Lund University, Swetox and SenzaGen reports its successful work on implementing a mathematical framework based on conformal prediction into GARD™ for the purpose of defining the applicability domain of the assay, something often neglected by test developers. Investigation of historical data within the framework demonstrates that all hitherto tested chemical reactivity domains, as well as pre- and pro-haptens are within the applicability domain of GARD, and can be predicted with a high degree of confidence. The results of this research demonstrate that the multivariate genomic biomarker signature, the unique technology of GARD makes it applicable across various chemical reactivity domains.

The mathematical framework in this implementation defines the applicability domain in terms of similarity to the samples used for model development and is capable of providing a statistically valid measure of uncertainty associated with each prediction. Furthermore, it also delivers a warning if a specific test sample is outside the region where the model is capable of generating a reliable prediction. Similar to the field of QSAR modelling, this information should be a minimal requirement for a successful validation also of in vitro models.

As the first in vitro model for prediction of skin sensitizing potential of chemicals, GARD™ is now capable of providing a statistically valid measure of uncertainty for each individual prediction, thus allowing for classification of skin sensitizers with even higher confidence. These scientific findings will benefit the chemical industry by providing better guidance of what test to use for different substances in different chemical domains and demonstrates the even broader applicability of GARD.

Full article:  Predicting skin sensitizers with confidence — Using conformal prediction to determine applicability domain of GARD Forreryd A., Norinder U., Lindberg T., Lindstedt M.  
https://www.sciencedirect.com/science/article/pii/S0887233318300237?via%3Dihub


For more information:
Anki Malmborg Hager, CEO, SenzaGen AB
Email: anki.malmborg.hager@senzagen.com
Telephone: +46 768 284822

 

About GARD™
GARD is a group of tests for assessing chemical skin sensitizers. The tests make use of genetic biomarkers for more than 200 genes which cover the entire immune reaction and are relevant to predicting the risk of hypersensitivity. The tests have over 90% reliability. This compares with the current predominant test method, experiments on mice, which has an accuracy of 70-75%. SenzaGen’s tests are also capable of measuring the potency of a substance’s allergenic properties. Consequently, GARD tests provide a much more comprehensive basis for determining whether a substance should be classified as an allergen than current testing methods.

About SenzaGen
SenzaGen makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals we come into contact with in our daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The company’s patented tests are the most reliable on the market and provide more information than traditional evaluation methods. We ourselves sell the tests in Sweden and the USA, and we sell through partners in several other countries. Over the next few years the company will expand geographically, make alliances with more distribution partners and launch further unique tests. SenzaGen has its headquarters in Lund in Sweden and a subsidiary in San Francisco, USA. For more information visit www.senzagen.com

News post as pdf